FINN Partners releases new whitepaper highlighting challenges for scaling the UK and European biotech and biopharma industry

PR Newswire
Today at 1:17pm UTC

FINN Partners releases new whitepaper highlighting challenges for scaling the UK and European biotech and biopharma industry

PR Newswire

  • Whitepaper released as part of London Life Sciences Week explores what is needed to overcome the challenges facing biotech and biopharma in the UK and Europe.
  • FINN Partners sets out the playbook on the role of communications in overcoming the most pressing challenges.

LONDON, Nov. 16, 2026 /PRNewswire/ -- Global independent marketing and communications firm FINN Partners has released a landmark whitepaper The Future of Biotech and Biopharma in the UK & Europe, published to coincide with London Life Sciences Week 2026.

FINN Partners logo

FINN Partners' new whitepaper highlighting challenges for scaling the UK and European biotech and biopharma industry

The whitepaper analyses the structural barriers standing in the way of UK and continental European life science companies from becoming globally dominant market players.

Sophie Taylor-Roberts, managing partner and UK health lead, FINN Partners, said: "UK and European life sciences ecosystems generate world-class innovations, but as we know scientific excellence is not enough on its own to guarantee commercial success. To redress the balance, we need to eliminate the transatlantic scaling gap."

"As investors and life sciences leaders meet at London Life Sciences Week, our whitepaper examines the impact of cross-border manufacturing bottlenecks, addresses the realities of NHS and single-payer reimbursement, and provides a framework for what needs to be done to ensure the future success of the industry in the UK and Europe."

The whitepaper looks specifically at the problem of transatlantic capital deficiency and scaling, overcoming post-Brexit difficulties in manufacturing of the product due to CDMO logistics, and addressing health technology assessments (HTAs) in the UK and European single-payer markets. It also focusses on mitigating the risks related to health data security in the era of generative artificial intelligence and machine learning technologies.

Highlights of the whitepaper include:

How to surmount structural growth challenges: Though the "Golden Triangle" of the UK (Oxford, Cambridge, London) and research clusters in Europe including BioRN, Basel and Medicon Valley generate world-class scientific research, there are often difficulties with growth financing and lab space shortages. The whitepaper suggests creating a "connected density" across Europe to establish an efficient ecosystem of capital, talent and fluid infrastructure.

Fortifying supply chain resilience and mitigating reputational damage: Biopharma often suffers from severe supply chain risks due to high customs barriers related to post-Brexit cross-border manufacturing. The whitepaper explores how supply chain and cold-chain resilience and local CDMO partnerships could be used as key commercial differentiators in the field.

Preparing health systems for complex, high-cost therapies: Demonstration of safety and efficacy alone is not enough for European adoption. To overcome cost thresholds set by the NHS in the UK, HAS in France and the G-BA in Germany, the whitepaper argues it is vital to adopt the right communications approach to unlock the systemic benefits of these products several years before launch.

Overcoming the data security challenge that AI brings: Due to the rapid advancement in computational biology and machine learning for drug discovery and design, data security has become a reputational and operational challenge. The whitepaper identifies ways to navigate this minefield.

Julian Tyndale-Biscoe, senior partner, UK health practice, FINN Partners, said: "The most difficult challenge faced by life sciences scale-ups is the transformation of complex science into business. Today, the industry faces unprecedented difficulties of logistics, governance and sensitivity of health data and increased regulatory scrutiny. Communication of operational resilience – whether in CDMO collaboration, cold-chain management or data privacy – must be paramount. It has become crucial for securing investors' confidence and preserving the reputation of the company."

Mark Chataway, managing partner, Health Policy and Impact at FINN Partners, said: "The European life sciences ecosystem should not be an incubator of its own intellectual property to be exported elsewhere. To increase regional competitiveness, it is necessary to use an integrated approach to health economics, policy and international regulation. If Europe wants life sciences companies to stay and to succeed on the continent, national health systems and innovation policy need to be more fluid. In addition, communication of the systemic value of innovations to regulatory and health authorities is vital for rapid access to life-saving medicines by patients."

The whitepaper is available free of charge at: https://www.finnpartners.com/news-insights/the-future-of-biotech-in-the-uk-europe/.

About FINN Partners
Founded in 2011 on the core principles of innovation and collaborative partnership, FINN Partners has grown from about $24 million in fees to almost $200 million in fees during the past 14 years, becoming one of the fastest-growing independent public relations agencies in the world. Recognized as one of Fast Company's 2024 Most Innovative Companies, PRovoke Media's 2024 Best Agency to Work For and 2022 Agency of the Year, the full-service marketing and communications company's record-setting pace results from organic growth and integrating new companies and new people into the FINN world through a common philosophy.

With more than 1,300 professionals across 39 offices, FINN provides clients with global access and capabilities in the Americas, Europe, and Asia. In addition, FINN provides its clients with access to top-tier agencies worldwide through its membership in the global network PROI.

Headquartered in New York, FINN has offices in: Abu Dhabi, Atlanta, Bangalore, Bangkok, Beijing, Boston, Chicago, Columbus, Delhi, Denver, Detroit, Dublin, Fort Lauderdale, Frankfurt, Hong Kong, Honolulu, Jerusalem, Kuala Lumpur, London, Los Angeles, Madison, Wisc., Manila, Melbourne, Minneapolis, Mumbai, Munich, Nashville, Orange County, Paris, Portland, San Diego, San Francisco, Seattle, Singapore, Sydney, Vancouver, Washington D.C. and Yangon. Find us at finnpartners.com and follow us on Instagram at @finnpartners.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/finn-partners-releases-new-whitepaper-highlighting-challenges-for-scaling-the-uk-and-european-biotech-and-biopharma-industry-302940430.html

SOURCE FINN Partners, Inc.